Asunercept

Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein (hIgG1) targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) [1][2][3].

Product Specifications

CAS Number

[1450882-18-4]

Product Name Alternative

APG101; CAN008

UNSPSC

12352203

Target

TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/asunercept.html

Purity

98.13

Solubility

10 mM in DMSO

Smiles

[Asunercept]

Molecular Weight

(84.05 kDa)

References & Citations

[1]Merz C, et al. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro. Anticancer Drugs. 2015 Aug;26 (7) :716-27. |[2]Krendyukov A, et al. Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies. Cancer Manag Res. 2019 Sep 2;11:8095-8100. |[3]Radujkovic A, et al. Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile. Cancers (Basel) . 2020 Dec 8;12 (12) :3683.